p53 Arg72Pro polymorphism and risk of basal cell carcinoma: a meta analysis.

Yanli Tian, Li Li, Rongya Yang

Abstract read

In one paragraph

Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yanli TianMedical School of Chinese PLA, The Chinese PLA General Hospital Beijing, China ; Department of Dermatology, The General Hospital of Beijing Military Command Beijing, China.

Li LiDepartment of Dermatology, The General Hospital of Beijing Military Command Beijing, China.

Rongya YangDepartment of Dermatology, The General Hospital of Beijing Military Command Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe attempted to comprehensively assess the possible association between p53 Arg72Pro polymorphism and the risk of basal cell carcinoma (BCC).

methodsWe performed a literature search of case-control association studies on p53 Arg72Pro polymorphism and BCC susceptibility in PubMed and EMBASE. 7 eligible studies were finally identified and their data were extracted for this meta-analysis. BCC risk was determined with the fixed effects model using a pooled odds ratio (OR).

resultsUsing distinct genetic models, we found that p53 Arg72Pro polymorphism was not associated with the overall risk of BCC. We observed a similar trend towards the association when performing subgroup analysis for Caucasians and Asians.

conclusionOur results suggest that presence of the common p53 Arg72Pro polymorphism may not play a role in the development of BCC. Larger studies are needed to better confirm the association.

Indexed as

BCCp53polymorphismrisk

Identifiers

PMID25932172

PMCPMC4402819

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.